Home    Back

Bms-986089    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
113Muscular dystrophy9

113. Muscular dystrophy    [ 567 clinical trials,   442 drugs,   (DrugBank: 93 drugs),   55 drug target genes,   151 drug target pathways]
Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
9 / 567 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2016-001654-18-DE
(EUCTR)		13/11/201723/06/2017Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular DystrophyA randomized, double blind, placebo-controlled, study to assess the efficacy, safety, and tolerability of RO7239361 in ambulatory boys with Duchenne Muscular dystrophy Duchenne Muscular Dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]		Product Name: RO7239361 Injections, 7.5 mg/Syringe (10.7 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin
Product Name: RO7239361 Injections, 15 mg/Syringe (21.4 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin
Product Name: RO7239361 Injections, 35 mg/Syringe (50 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin
Product Name: RO7239361 Injections, 50 mg/Syringe (71.4 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin		F. Hoffmann-La Roche LtdNULLNot RecruitingFemale: no
Male: yes		159Phase 3United States;Spain;United Kingdom;Italy;France;Canada;Argentina;Belgium;Australia;Germany;Netherlands;Japan;Sweden
2EUCTR2016-001654-18-BE
(EUCTR)		10/11/201726/06/2017Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 (BMS-986089) in Ambulatory Boys With Duchenne Muscular DystrophyA randomized, double blind, placebo-controlled, study to assess the efficacy, safety, and tolerability of RO7239361 (BMS-986089) in ambulatory boys with Duchenne Muscular dystrophy Duchenne Muscular Dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]		Product Name: BMS-986089-01 (RO7239361) Injections, 7.5 mg/Syringe (10.7 mg/mL)
Product Code: RO7239361 (BMS-986089)
INN or Proposed INN: Anti-myostatin Adnectin
Other descriptive name: BMS-986089-01 (RO7239361) , anti-myostatin
Product Name: BMS-986089-01 (RO7239361) Injections, 15 mg/Syringe (21.4 mg/mL)
Product Code: RO7239361 (BMS-986089)
INN or Proposed INN: Anti-myostatin Adnectin
Other descriptive name: BMS-986089-01 (RO7239361), anti-myostatin
Product Name: BMS-986089-01 (RO7239361) Injections, 35 mg/Syringe (50 mg/mL)
Product Code: RO7239361 (BMS-986089)
INN or Proposed INN: Anti-myostatin Adnectin
Other descriptive name: BMS-986089-01 (RO7239361), anti-myostatin
Product Name: BMS-986089-01 (RO7239361) Injections, 50 mg/Syringe (71.4 mg/mL)
Product Code: RO7239361 (BMS-986089)
INN or Proposed INN: Anti-myostati		F. Hoffmann-La Roche LtdNULLNot RecruitingFemale: no
Male: yes		159Phase 3United States;Spain;Italy;United Kingdom;France;Canada;Argentina;Belgium;Australia;Germany;Netherlands;Japan;Sweden
3EUCTR2016-001654-18-FR
(EUCTR)		10/11/201730/10/2017Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular DystrophyA Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys with Duchenne Muscular Dystrophy Duchenne Muscular Dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]		Product Name: BMS-986089-01 Injections, 7.5 mg/Syringe (10.7 mg/mL)
Product Code: BMS-986089
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin
Product Name: BMS-986089-01 Injections, 15 mg/Syringe (21.4 mg/mL)
Product Code: BMS-986089
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin
Product Name: BMS-986089-01 Injections, 35 mg/Syringe (50 mg/mL)
Product Code: BMS-986089
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin
Product Name: BMS-986089-01 Injections, 50 mg/Syringe (71.4 mg/mL)
Product Code: BMS-986089
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin		Bristol-Myers Squibb International CorporationNULLNot RecruitingFemale: no
Male: yes		160Phase 3United States;Spain;Italy;United Kingdom;France;Canada;Argentina;Belgium;Australia;Germany;Netherlands;Japan;Sweden
4EUCTR2016-001654-18-GB
(EUCTR)		01/11/201727/06/2017Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular DystrophyA Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys with Duchenne Muscular Dystrophy Duchenne Muscular Dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]		Product Name: RO7239361 Injections, 7.5 mg/Syringe (10.7 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, Anti-myostatin
Product Name: RO7239361 Injections, 15 mg/Syringe (21.4 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin
Product Name: RO7239361 Injections, 35 mg/Syringe (50 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin
Product Name: RO7239361 Injections, 50 mg/Syringe (71.4 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin		F. Hoffmann-La Roche LtdNULLNot RecruitingFemale: no
Male: yes		159Phase 3United States;Spain;United Kingdom;Italy;France;Canada;Argentina;Belgium;Australia;Germany;Netherlands;Japan;Sweden
5EUCTR2016-001654-18-NL
(EUCTR)		26/10/201712/07/2017Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular DystrophyA Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys with Duchenne Muscular Dystrophy Duchenne Muscular Dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]		Product Name: RO7239361 Injections, 7.5 mg/Syringe (10.7 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, Anti-myostatin
Product Name: RO7239361 Injections, 15 mg/Syringe (21.4 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin
Product Name: RO7239361 Injections, 35 mg/Syringe (50 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin
Product Name: RO7239361 Injections, 50 mg/Syringe (71.4 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin		F. Hoffmann-La Roche LtdNULLNot RecruitingFemale: no
Male: yes		159Phase 3United States;Spain;Italy;United Kingdom;France;Canada;Argentina;Belgium;Australia;Netherlands;Germany;Japan;Sweden
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2016-001654-18-IT
(EUCTR)		19/09/201707/02/2018Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular DystrophyA Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys with Duchenne Muscular Dystrophy - - Duchenne Muscular Dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]		Product Name: BMS-986089-01 Injections, 7.5 mg/Syringe (10.7 mg/mL)
Product Code: BMS-986089
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin
Product Name: BMS-986089-01 Injections, 15 mg/Syringe (21.4 mg/mL)
Product Code: BMS-986089
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin
Product Name: BMS-986089-01 Injections, 35 mg/Syringe (50 mg/mL)
Product Code: BMS-986089
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin
Product Name: BMS-986089-01 Injections, 50 mg/Syringe (71.4 mg/mL)
Product Code: BMS-986089
INN or Proposed INN: Anti-Myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin		BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIONNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes		160Phase 3United States;Spain;Italy;United Kingdom;France;Canada;Argentina;Belgium;Australia;Germany;Netherlands;Japan;Sweden
7EUCTR2016-001654-18-ES
(EUCTR)		04/09/201704/07/2017Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular DystrophyA Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys with Duchenne Muscular Dystrophy Duchenne Muscular Dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]		Bristol-Myers Squibb International CorporationNULLNot Recruiting Female: no
Male: yes		160Phase 3United States;Spain;United Kingdom;Italy;France;Canada;Argentina;Belgium;Australia;Germany;Netherlands;Japan;Sweden
8EUCTR2016-001654-18-SE
(EUCTR)		12/08/201715/06/2017Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular DystrophyA randomized, double blind, placebo-controlled, study to assess the efficacy, safety, and tolerability of RO7239361 in ambulatory boys with Duchenne Muscular dystrophy Duchenne Muscular Dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]		Product Name: RO7239361 Injections, 7.5 mg/Syringe (10.7 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-myostatin Adnectin
Other descriptive name: BMS-986089-01, Anti-myostatin
Product Name: RO7239361 Injections, 15 mg/Syringe (21.4 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin
Product Name: RO7239361 Injections, 35 mg/Syringe (50 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin
Product Name: RO7239361 Injections, 50 mg/Syringe (71.4 mg/mL)
Product Code: RO7239361
INN or Proposed INN: Anti-myostatin Adnectin
Other descriptive name: BMS-986089-01, anti-myostatin		F. Hoffmann-La Roche LtdNULLNot RecruitingFemale: no
Male: yes		159Phase 3United States;Spain;Italy;United Kingdom;France;Canada;Argentina;Belgium;Australia;Germany;Netherlands;Japan;Sweden
9NCT02515669
(ClinicalTrials.gov)		December 2, 201529/7/2015Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMDA Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7239361 (BMS-986089) in Ambulatory Boys With Duchenne Muscular DystrophyMuscular Dystrophy (DMD)Drug: RO7239361;Drug: PlaceboHoffmann-La RocheNULLTerminated5 Years10 YearsMale43Phase 1;Phase 2United States;Canada

Back to top